Catálogo de publicaciones - libros

Compartir en
redes sociales

36th Hemophilia Symposium: Hamburg 2005

Inge Scharrer ; Wolfgang Schramm (eds.)

Resumen/Descripción – provisto por la editorial

No disponible.

Palabras clave – provistas por la editorial

Medicine & Public Health;

Institución detectada Año de publicación Navegá Descargá Solicitá
No detectada 2007 SpringerLink


Tipo de recurso:


ISBN impreso


ISBN electrónico


Editor responsable

Springer Nature

País de edición

Reino Unido

Fecha de publicación

Tabla de contenidos

Spectrum of Molecular Defects and Mutation Detection Rate in Patients with Mild and Moderate Hemophilia A

N. Bogdanova; A. Markoff; U. Nowak-Göttl; R. Eisert; C. Wermes; H. Pollmann; A. Todorova; A. Eigel; B. Dworniczak; J. Horst

Palabras clave: Factor VIII; Molecular Defect; Severe Hemophilia; Coagulation Factor VIII; Mutation Detection Rate.

Pp. 129-132

Recombinant Factor VIIa for Major Surgery in Severe Factor XI Deficiency: Pharmacodynamic Monitoring Using Thromboelastometry

H. Dehmel; J. Priesack; R. Eisert; A. Tiede

Palabras clave: Recombinant Factor VIIa; Major Procedure; Coagulation Factor Viii; FVIII Inhibitor; Rotation Thromboelastometry.

Pp. 133-136

Establishment of a Web-Based Documentation System for Quality Assurance of Hemophilia Treatment in Mecklenburg/Western Pomeranian: a Pilot Study

B. Steiner; P. Bruhn; B. Berthold; D. Hähling; B. Meyer; A. Grainacher; F. Herrmann; U. Kyank; B. Gombert; C. Burstein; M. Freund

Pp. 139-139

Successful Angiographic Embolization of Recurrent Elbow Joint Bleeds in one Patient with Severe Hemophilia A

R. Klamroth; S. Gottstein; E. Essers; M. Orlovic; M. Wilaschek

In joint bleeds not responding to substitution of factor VIII to normal factor VIII levels angiographic embolization might be considered as a therapeutic option, especially if surgical treatment is not possible. Embolization with embolization fluid might be more promising than use of microparticles, because microparticles are resolving after 8 weeks and there is the danger of insufficient thrombosis and reopening of the vessel in patients with severe hemophilia.

Palabras clave: Factor Viii; Elbow Joint; Recombinant Factor Viii; Ulnar Artery; Severe Hemophilia.

Pp. 140-143

Evaluation of Thrombotic Events in Hemophiliacs Undergoing Major Orthopedic Surgery Without Thrombosis Prophylaxis

M. Krause; Ch. von Auer; A. Kurth; M. Böhm; L. Hovy; I. Scharrer

Palabras clave: Factor VIII; Venous Thromboembolism; Knee Replacement; Thrombotic Event; Thrombosis Prophylaxis.

Pp. 144-146

Motivating Patients and Parents to Document Treatment Correctly

S. Jenkins

Pp. 147-149

Fit for Life Competition: Everyone’s a Winner

A. Seuser; G. Auerswald; W. Eberl; S. Gutsche; P. Böhm; R. Klamroth; A. Kurme

Palabras clave: Aerobic Fitness; Focal Epilepsy; Back Muscle; Individual Team; Team Score.

Pp. 150-152

Blood Borne Infections in Hemophiliacs in a Developing Country. A Single Center Experience

M. Serban; M. Pop; St. Jenariu; L. Pop; C. Jinca; D. Mihailov; S. Arghirescu; M. Bătăneant; W. Schramm

NBP are still a factor of concern in patients with hemophilia despite the more efficient screening methods introduced in the last decade in our country. From this perspective, clotting factor concentrates are much more efficient and safe, but the limited access to them in our patients makes imperative to use the combination with CPP or FFP.Mandatory vaccination against HBV and the introduction of serological screening methods for donors in Romania after 1993 has led to the decrease of the risk for hepatitis transmission.

Palabras clave: Viral Load; Fresh Freeze Plasma; Hemophilia Patient; Native Blood; Main Treatment Modality.

Pp. 153-158

Hemophilia Center Frankfurt - Twinning Center for Nairobi/Kenya

W. Miesbach; G. Asmelash; M. Boehm; I. Scharrer

Palabras clave: Factor VIII; Laboratory Diagnosis; Staff Exchange; Senior Consultant; Hemophilia Patient.

Pp. 159-160

Economic Evaluation of Orthopedic and Surgical Interventions in Hemophiliacs - Not Only Direct Medical Costs Matter

D. Mihailov; M. Serban; R. Badeti; P. Tepeneu; W. Schramm; D. Lighezan

Palabras clave: Direct Medical Cost; Hemophilia Patient; Catastrophic Health Expenditure; Titer Inhibitor; Substitution Cost.

Pp. 161-167